IRulya Therapeutics Inc.

IRLA · XNAS

CIK 1662774fmd_19E4P0V42K43F0WRQ1HK5F10N9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2018 to Jun 30, 2026, 34 periods

AI-written

A model wrote this from the company's own SEC filings and our standardized facts. It is not reported fact, not an analyst's estimate, not a rating and not investment advice. Every claim shows what it rests on.